KCD drug combination for newly diagnosed POEMS syndrome
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with POEMS syndrome (a rare blood disorder).
- You should be between 18 and 75 years old.
- Your vital organs (kidneys, liver, heart) must be working well enough based on blood tests and heart checks.
- You cannot have had any prior treatment for POEMS syndrome, except possibly steroids.
- You must not have a serious active infection or other unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells (genetically engineered immune cells) to treat POEMS syndrome that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment can help reduce symptoms and control the disease.
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
This trial tests a new combination of medicines (SonKRd) for people who have just been diagnosed with multiple myeloma and have a specific genetic change called t(11;14). The goal is to see if this treatment works well before a stem cell transplant.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Hear when a new POEMS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.